IP Library › Granted Patent US 11,237,165
Granted Patent B2
US 11,237,165 · App. 15/652,827 · Granted Feb 1, 2022

Antibody producing non-human animals

Inventors: Ton Logtenberg (Utrecht, NL); Mark Throsby (Utrecht, NL); Robert A. Kramer (Utrecht, NL); Rui Daniel Pinto (Utrecht, NL); Cornelis A. de Kruif (De Bilt, NL); Erwin Houtzager (Zeist, NL)
Assignee: Merus N.V.
G01N33/56966C07K16/00C07K16/005C07K16/10C07K16/22C07K16/248C07K16/2863C07K16/32C07K2317/10C07K2317/14C07K2317/21C07K2317/24C07K2317/31C07K2317/34C07K2317/51C07K2317/515C07K2317/52C07K2317/55C07K2317/56C07K2317/622C07K2317/64C07K2317/76C07K2317/94C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,237,165
App. No.
15/652,827
Granted
Feb 1, 2022
Kind
B2
Abstract

Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

Claims (22)

1. A method for selecting a single recombinant cell that expresses at least a bispecific antibody, or antibody fragment thereof, the method comprising:

providing recombinant cells comprising at least two different heavy chain variable regions and a light chain variable region, wherein the at least two different heavy chain variable regions are encoded by nucleic acid sequences obtained from a transgenic non-human animal, and wherein the light chain variable region is able to functionally pair with more than one heavy chain variable region,

pairing of the variable regions and secretion of the paired variable regions from the recombinant cells resulting in the production of the bispecific antibody,

and

selecting a single recombinant cell from the recombinant cells that produces a bispecific antibody that binds two target epitopes,

wherein the light chain variable region comprises a V and J consisting of germline sequences encoded by a human immunoglobulin light chain V gene segment joined to a human immunoglobulin light chain J gene segment.

2. The method according to claim 1 , wherein the two target epitopes are associated with a disease and/or disorder.

3. The method according to claim 1 , wherein the light chain variable region able to functionally pair with more than one heavy chain variable region does not significantly contribute to the resulting binding specificity of the resulting paired regions.

4. The method according to claim 1 , wherein the recombinant cells comprise at least four variable regions.

5. The method according to claim 1 , wherein one of the heavy chain variable regions and the light chain variable region are part of one single chain Fv.

6. The method according to claim 1 , wherein the single recombinant cell expresses at least a bispecific antibody and a monospecific antibody.

7. The method according to claim 1 , wherein the sequence encoding the light chain variable region is obtained from the transgenic non-human animal.

8. The method according to claim 1 , wherein a first heavy chain variable region is obtained by immunizing a first non-human animal with a first target epitope of the two target epitopes and wherein a second heavy chain variable region is obtained by immunizing a second non-human animal with a second target epitope of the two target epitopes.

9. The method according to claim 1 ,

wherein the genome of the transgenic non-human animal comprises a transgene comprising a human immunoglobulin light chain V gene segment joined to a human immunoglobulin light chain J gene segment,

wherein the joined human V/J gene segment encodes a human immunoglobulin light chain variable region, and

wherein the transgenic non-human animal, in response to exposure to a target epitope, produces antibodies with immunoglobulin light chains comprising the human light chain variable region encoded by the transgene and a light chain constant region, paired with a diversity of immunoglobulin heavy chains which bind the target epitope.

10. The method according to claim 1 , wherein the transgenic non-human animal is a murine animal.

11. The method according to claim 1 , wherein the transgenic non-human animal is a mouse.

12. The method according to claim 1 , wherein the recombinant cells comprise two different heavy chain variable regions.

13. The method according to claim 1 , wherein the recombinant cells comprise four variable regions.

14. The method according to claim 13 , wherein the recombinant cells comprise a common light chain variable region.

Assignments (4)
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2017
From: HOUTZAGER, ERWIN
To: MERUS B.V.
Reel/Frame 043467/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: HOOGENBOOM, HENDRICUS RENERUS; LOGTENBERG, TON; THROSBY, MARK; KRAMER, ROBERT A.; PINTO, RUI DANIEL; DE KRUIF, CORNELIS A.
To: MERUS B.V.
Reel/Frame 043241/0001 →
CHANGE OF NAME Recorded Jul 19, 2017
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 043402/0147 →
Continuity (5)
Continuation 15140321 · Apr 27, 2016
Continuation 12589181 · Oct 19, 2009
Continuation 12459285 · Jun 29, 2009
Provisional Application 61133274 · Jun 27, 2008
Related Publication 20180031555A1 · Feb 1, 2018
Cited By (1)
US 12,291,798